Fig. 1

Animal survival after treatment with IRE and/or anti-PD1. a Treatment schedule and a photograph showing the placement of the two-electrode IRE array in the KRAS* tumor. C57BL/6 mice bearing orthotopic KRAS* tumors were enrolled for treatment once tumor size reached about 7 mm in one dimension. Sham surgery was performed on both control and anti-PD1 treatment groups. b Kaplan–Meier survival analysis of mice with KRAS* tumor treated with sham control (black solid circle, n = 8), IRE (black circle, n = 8), anti-PD1 (blue solid triangle, n = 8), or IRE + anti-PD1 (blue triangle, n = 11). ****p < 0.0001, log-rank test. c Survival analysis of B16F10-bearing mice treated with sham control (n = 10), IRE (n = 10), anti-PD1 (n = 10), or IRE + anti-PD1 (n = 10). ****p < 0.0001, log-rank test. d Representative axial T₂-MRI images of a KRAS*-bearing mouse from each group in a separate small-scale study. Three mice per group were enrolled in the sham control, anti-PD1, and IRE groups; 5 mice were enrolled in the IRE + anti-PD1 group. Treatment started on day 0. MRI slices with the largest tumor cross-section are presented to show tumor size at each time point. The entire extent of the tumor is outlined with yellow dashed lines. MRI images were acquired weekly until the mice were euthanized due to excessive tumor burden. The surviving mice in the IRE + anti-PD1 group were imaged until day 42 (Supplementary Figure 6). Scale bar = 5 mm. Source data are provided as a Source Data file